268 related articles for article (PubMed ID: 37166701)
1. Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Radonjić NV; Bellato A; Khoury NM; Cortese S; Faraone SV
CNS Drugs; 2023 May; 37(5):381-397. PubMed ID: 37166701
[TBL] [Abstract][Full Text] [Related]
2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST; Steeves TD; Pringsheim T
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
[TBL] [Abstract][Full Text] [Related]
6. Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Pan PY; Jonsson U; Şahpazoğlu Çakmak SS; Häge A; Hohmann S; Nobel Norrman H; Buitelaar JK; Banaschewski T; Cortese S; Coghill D; Bölte S
Psychol Med; 2022 Jan; 52(1):14-25. PubMed ID: 34635194
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.
Pringsheim T; Steeves T
Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404
[TBL] [Abstract][Full Text] [Related]
9. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Chan D; Childress A
J Manag Care Spec Pharm; 2024 Jun; 30(6):528-540. PubMed ID: 38824626
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
[TBL] [Abstract][Full Text] [Related]
11. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
Price MZ; Price RL
CNS Drugs; 2023 Jul; 37(7):655-660. PubMed ID: 37430151
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder.
Childress A; Burton S
Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):357-366. PubMed ID: 35848085
[TBL] [Abstract][Full Text] [Related]
14. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.
Raible H; D'Souza MS
Ann Pharmacother; 2023 Dec; 57(12):1436-1448. PubMed ID: 37021356
[TBL] [Abstract][Full Text] [Related]
15. Nonstimulant Treatments for ADHD.
Newcorn JH; Krone B; Dittmann RW
Child Adolesc Psychiatr Clin N Am; 2022 Jul; 31(3):417-435. PubMed ID: 35697393
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants.
Childress A
Expert Opin Pharmacother; 2024 May; 25(7):853-866. PubMed ID: 38771653
[TBL] [Abstract][Full Text] [Related]
17. Guanfacine for the Treatment of Attention-Deficit Hyperactivity Disorder: An Updated Systematic Review and Meta-Analysis.
Yu S; Shen S; Tao M
J Child Adolesc Psychopharmacol; 2023 Mar; 33(2):40-50. PubMed ID: 36944092
[No Abstract] [Full Text] [Related]
18. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Otasowie J; Castells X; Ehimare UP; Smith CH
Cochrane Database Syst Rev; 2014 Sep; (9):CD006997. PubMed ID: 25238582
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
20. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Epstein T; Patsopoulos NA; Weiser M
Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
